LINC00885 promotes lung squamous cell carcinoma by upregulating SLBP expression to activate PI3K/Akt pathway

Lung squamous cell carcinoma (LUSC) remains an aggressive malignancy with limited therapeutic options and poor prognosis. Understanding the molecular drivers of LUSC pathogenesis is crucial for developing novel interventions. This study investigates the functional significance and mechanistic basis of long non-coding RNA LINC00885 in LUSC progression. We employed integrated methodologies including bioinformatic analysis, clinical specimen validation, in vitro functional assays (EdU incorporation, colony formation, Transwell migration/invasion), molecular profiling (qPCR, immunoblotting, northern blot, fluorescence in situ hybridization, subcellular fractionation), mechanistic investigations (chromatin isolation by RNA purification, luciferase reporter assays), and in vivo xenograft modeling. LINC00885 was significantly upregulated in LUSC clinical tissues and cell lines. Genetic depletion of LINC00885 suppressed malignant phenotypes including cellular proliferation, migration, invasion, and epithelial-mesenchymal transition. Mechanistically, LINC00885 directly bound and repressed tumor-suppressive miR-654-3p, which targeted stem-loop binding protein (SLBP). LINC00885 activated PI3K/Akt signaling through SLBP upregulation, and either SLBP overexpression or miR-654-3p depletion rescued the tumor-suppressive effects of LINC00885 knockdown. Xenograft models confirmed LINC00885 silencing significantly inhibited tumor growth in vivo. LINC00885 promotes LUSC progression via the miR-654-3p/SLBP/PI3K/Akt signaling axis.

Authors

Institutions

Publication Details

Journal
Clinical and Experimental Medicine
Published
2025-10-25
DOI
https://doi.org/10.1007/s10238-025-01863-0
Citations
1
Primary Topic
Cancer-related molecular mechanisms research
Type
article
Field-Weighted Citation Impact
0.94
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

LINC00885 promotes lung squamous cell carcinoma by upregulating SLBP expression to activate PI3K/Akt pathway

Zhilong Xi, Jin‐Song Bian, Xiao Dong He, Weinan Li et al.
1 citations
Clinical and Experimental Medicine
Cancer-related molecular mechanisms research
0.94
article

LINC00885 promotes lung squamous cell carcinoma by upregulating SLBP expression to activate PI3K/Akt pathway

Zhilong Xi, Jin‐Song Bian, Xiao Dong He, Weinan Li, Wei Lei, Lele Wang
article en
1 citations

Abstract

Lung squamous cell carcinoma (LUSC) remains an aggressive malignancy with limited therapeutic options and poor prognosis. Understanding the molecular drivers of LUSC pathogenesis is crucial for developing novel interventions. This study investigates the functional significance and mechanistic basis of long non-coding RNA LINC00885 in LUSC progression. We employed integrated methodologies including bioinformatic analysis, clinical specimen validation, in vitro functional assays (EdU incorporation, colony formation, Transwell migration/invasion), molecular profiling (qPCR, immunoblotting, northern blot, fluorescence in situ hybridization, subcellular fractionation), mechanistic investigations (chromatin isolation by RNA purification, luciferase reporter assays), and in vivo xenograft modeling. LINC00885 was significantly upregulated in LUSC clinical tissues and cell lines. Genetic depletion of LINC00885 suppressed malignant phenotypes including cellular proliferation, migration, invasion, and epithelial-mesenchymal transition. Mechanistically, LINC00885 directly bound and repressed tumor-suppressive miR-654-3p, which targeted stem-loop binding protein (SLBP). LINC00885 activated PI3K/Akt signaling through SLBP upregulation, and either SLBP overexpression or miR-654-3p depletion rescued the tumor-suppressive effects of LINC00885 knockdown. Xenograft models confirmed LINC00885 silencing significantly inhibited tumor growth in vivo. LINC00885 promotes LUSC progression via the miR-654-3p/SLBP/PI3K/Akt signaling axis.

Clinical and Experimental MedicineVol. 25(1)
Second Affiliated Hospital of Nanjing Medical University (CN), Nanjing Medical University (CN), Nanjing University (CN)
Openalex Percentile: Top 19%
Cancer-related molecular mechanisms research
0.94
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.